posted                      

Health/Medical Writers / Business Editors MONTGOMERY, Texas--(BUSINESS WIRE)--EVSC-- Endovasc Inc. (OTCBB: EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today that its first clinical site in the Republic of Georgia has already identified and prescreened 18 candidates. These patients, who suffer from peripheral vascular disease (PVD), but do not require angioplasty, have already undergone a series of tests and will be treated with Liprostin as soon as the drug is received. Dr. Diane Dottavio, Vice President of Research and Development, stated, "We have arranged with Pyramid Labs, Costa Mesa, CA, to have Liprostin shipped to the Georgian Angiology and Vascular Center on Monday, November 24. In speaking with Dr. Mamuka Bokuchava, principal investigator, he reported that at least fifteen patients have been prescreened and have already undergone preliminary tests to measure their pain free walking distance." Endovasc's multi-center, 120-patient, open-label, phase II clinical trial will measure PVD patients' walking distance and leg pain over the three-month duration of the trial. The multinational trial is being supervised by Dr. Fred Lowrey of Pharm-Olam International's Houston office. According to Dr. David Summers, Endovasc Chairman and CEO, "The start of this trial marks a significant milestone in the development of Liprostin. We are extremely excited, as we will be able to monitor the progress of these patients for the duration of the three-month trial period. We feel confident that we will see a positive trend in the patient population indicating the efficacy of Liprostin." More than 750,000 people in the United States suffer from Critical limb ischemia, which leads to amputation for approximately 200,000 people per year. Up to 10 million people in the United States suffer from severe leg pain (claudication) and non-healing ulcers, both of which result from CLI. Peripheral vascular disease is linked to cardiovascular disease in general, and is often associated with atherosclerosis, diabetes, lifestyle and aging. CLI is a very severe condition of peripheral vascular disease; there are currently no drugs approved for its treatment. Safe Harbor Statement The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com. KEYWORD: TEXAS INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL PHARMACEUTICAL SOURCE: Endovasc Inc. CONTACT INFORMATION: FOCUS Partners LLC David Zazoff, 212-752-9445 evsc@focuspartners

Posts: 1656 | Registered: Sep 2004  |  IP: Logged | 

posted                      

------------------
DaDog

Posts: 1656 | Registered: Sep 2004  |  IP: Logged | 

posted                      

...and a cigarette too ofcourse

Posts: 299 | From: Tuscaloosa, AL, USA! | Registered: Sep 2003  |  IP: Logged | 

posted                      

Are you guys doing to hold this one for the rest of the week or what?

Posts: 299 | From: Tuscaloosa, AL, USA! | Registered: Sep 2003  |  IP: Logged | 

posted                      

------------------
DaDog

Posts: 1656 | Registered: Sep 2004  |  IP: Logged | 

posted                      

All right ask is up to .3 now
We should start seeing a pick up with this one if not in the 20min then through the end of the day

Posts: 412 | From: Tucson, AZ USA | Registered: Dec 2003  |  IP: Logged | 

posted                      

fusion4you@aol.com

Posts: 299 | From: Tuscaloosa, AL, USA! | Registered: Sep 2003  |  IP: Logged |